Buch, Englisch, 467 Seiten, Previously published in hardcover, Format (B × H): 178 mm x 254 mm, Gewicht: 909 g
Buch, Englisch, 467 Seiten, Previously published in hardcover, Format (B × H): 178 mm x 254 mm, Gewicht: 909 g
Reihe: Pathology and Laboratory Medicine
ISBN: 978-1-61737-319-0
Verlag: Humana Press
In this greatly enlarged and thoroughly updated edition of his much praised Cardiac Markers, Alan Wu and his contributors focus on the use of markers in the practice of cardiology and-for the first time-on the use of natriuretic peptides for congestive heart failure. Here, leading international authorities in clinical chemistry and laboratory medicine, cardiology, emergency medicine, and the in vitro diagnostics industry describe the state-of-the-art uses of cardiac markers when treating coronary artery disease, and discuss in detail how they may be optimally used in a clinical setting. Comprehensive and cutting-edge, Cardiac Markers, Second Edition offers physicians a complete guide to the use of cardiac markers in clinical practice and clinical laboratorians a close-up view of the new markers now becoming standard.
Zielgruppe
Professional/practitioner
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Labormedizin
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pathologie, Cytopathologie, Histopathologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Kardiologie, Angiologie, Phlebologie
Weitere Infos & Material
I. Cardiac Markers in Clinical Practice.- 1 Early Detection of Myocardial Necrosis in the Emergency Setting and Utility of Serum Biomarkers in Chest Pain Unit Protocols.- 2 Management of Acute Coronary Syndromes.- 3 Evolution of Cardiac Markers in Clinical Trials.- 4 Assessing Reperfusion and Prognostic Infarct Sizing with Biochemical Markers: Practice and Promise.- 5 The Use of Cardiac Biomarkers to Detect Myocardial Damage Induced by Chemotherapeutic Agents.- 6 The Use of Biomarkers to Provide Diagnostic and Prognostic Information Following Cardiac Surgery.- II. Clinical Use for Cardiac Troponins.- 7 Cardiac Troponins: Exploiting the Diagnostic Potential of Disease-Induced Protein Modifications.- 8 Cardiac Troponin Testing in Renal Failure and Skeletal Muscle Disease Patients.- 9 Cardiac-Specific Troponins Beyond Ischemic Heart Disease.- III. Analytical Issues for Cardiac Markers.- 10 Antibody Selection Strategies in Cardiac Troponin Assays.- 11 Interferences in Immunoassays for Cardiac Troponin.- 12 Cardiac Marker Measurement by Point-of-Care Testing.- 13 Standardization of Cardiac Markers.- 14 Analytical Issues and the Evolution of Cutoff Concentrations for Cardiac Markers.- IV. Early Cardiac Markers of Myocardial Ischemia and Risk Stratification.- 15 Rationale for the Early Clinical Application of Markers of Ischemia in Patients with Suspected Acute Coronary Syndromes.- 16 Ischemia-Modified Albumin, Free Fatty Acids, Whole Blood Choline, B-Type Natriuretic Peptide, Glycogen Phosphorylase BB, and Cardiac Troponin.- 17 C-Reactive Protein for Primary Risk Assessment.- 18 Prognostic Role of Plasma High-Sensitivity C-Reactive Protein Levels in Acute Coronary Syndromes.- 19 Preanalytic and Analytic Sources of Variations in C-Reactive Protein Measurement.- 20 Fatty Acid Binding Protein as an Early Plasma Marker of Myocardial Ischemia and Risk Stratification.- 21 Oxidized Low-Density Lipoprotein and Malondialdehyde-Modified Low-Density Lipoprotein in Patients with Coronary Artery Disease.- V. Cardiac Markers of Congestive Heart Failure.- 22 Pathophysiology of Heart Failure.- 23 B-Type Natriuretic Peptide: Biochemistry and Measurement.- 24 B-Type Natriuretic Peptide in the Diagnoses and Management of Congestive Heart Failure.- 25 Monitoring Efficacy of Treatment with Brain Natriuretic Peptide.- 26 N-Terminal Pro-B-Type Natriuretic Peptide.- VI. Role of Infectious Diseases and Genetics in Heart Disease.- 27 Infectious Diseases in the Etiology of Atherosclerosis and Acute Coronary Syndromes: Focus on Chlamydia pneumoniae.- 28 Polymorphisms Related to Acute Coronary Syndromes and Heart Failure: Potential Targets for Pharmacogenomics.
